Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
关键词
抽象
描述
Patients with advanced cirrhosis frequently develop dilutional hyponatremia due to impairment of their renal ability to eliminate solute-free water. Although the pathophysiology of this disorder is multifactorial, an increased hypersecretion of arginine vasopressin (AVP) is a major factor. The prevalence of hyponatremia in cirrhosis, as defined by a serum sodium level of 130 mmol/L is reported to be about 20%, and there are several lines of evidence that hyponatremia is a risk factor for the development of hepatic encephalopathy, and that it predicts a poor quality of life independent of liver function. Hyponatremia also predicts short-term mortality in cirrhotic patients awaiting liver transplantation. The principle of the management of hypervolemic hypona- tremia is to induce a negative water balance, with the aim of normalizing the increased total body water, which would result in an improvement in serum sodium concentration. Fluid restriction is the most widely accepted nonpharmacological therapy, but its efficacy is very limited. The administration of hypertonic sodium chloride has been common in severe hypervolemic hyponatremia, but its effect is only partial and short lived; moreover, additional expansion of fluid can worsen ascites and edema. Therefore, the pathophysiologically oriented treatment of hyponatremia focuses on inhibiting the actions of AVP. Recently, antagonists of the V2 receptors of vasopressin has been proposed to manage hyponatremic patients, such as heart fauilure, syndrome of inappropriate antidiuretic hormone or liver cirrhosis. Especially, a lot of hyponatremic patients with cirrhosis had ascites, and some of them had intractable ascites. In these patients, antagonists of the V2 receptors of vasopressin including tolvaptan might have beneficial effect in enhancing not only hyponatremia , but also ascites
日期
| 最后验证: | 09/30/2012 |
| 首次提交: | 10/17/2012 |
| 提交的预估入学人数: | 10/28/2012 |
| 首次发布: | 10/29/2012 |
| 上次提交的更新: | 10/28/2012 |
| 最近更新发布: | 10/29/2012 |
| 实际学习开始日期: | 10/31/2012 |
| 预计主要完成日期: | 12/31/2013 |
| 预计完成日期: | 01/31/2014 |
状况或疾病
干预/治疗
Drug: Tolvaptan group
Drug: Placebo group
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Active Comparator: Tolvaptan group Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days | Drug: Tolvaptan group 15 - 60 mg/day for 28 days |
| Placebo Comparator: Placebo group Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days | Drug: Placebo group |
资格标准
| 有资格学习的年龄 | 20 Years 至 20 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: 1. 20 years of age or older 2. Patients with cirrhosis as diagnosed by liver biopsy or a combination of laboratory (thrombocytopenia), radiologic (cirrhotic feature of liver, splenomegaly, collateral shunt on US, CT, or MRI) and endoscopic findings (gastoesophageal varices or portal hypertensive gastropathy) 3. ≥ Grade 2 ascites who have already been treated with restricted salt diet within 3 month 4. Hyponatremia (Serum sodium ≥120 mEq/L and ≤130 mEq/L) 5. Written informed consent Exclusion Criteria: 1. Hypovolemic hyponatremia (Patients with hypotension or chronic heart failure) 2. Serum potassium concentration > 5.5 mEq/L 3. Serum bilirubin > 5.0 mg/dL 4. Blood coagulation factor < 40% or international normalized ratio (INR) > 2.3 5. Platelet count < 30,000/mm3 6. Serum creatinine > 3 mg/dL 7. Treatment within 2 weeks with vasopressin anlogues 8. Systolic blood pressure <80 mmHg 9. History of gastrointestinalesophageal varix bleeding variceal hemorrhage 10. Spontaneous bacterial peritonitis 11. Hepatic encephalopathy ≥ grade 3 12. History of Hepatocellular carcinoma treatment within 3month or viable tumor Viable hepatocellular carcinoma 13. Liver transplant 14. Previous treatment with transjugular intrahepatic portosystemic stent shunt (TIPS) 15. History of significant cardiac diseases such as recent myocardial infarction or ischemic diseases within 1 year of screening 16. Prolonged QTc interval of > 500 ms based on electrocardiography 17. Treatment within 2 weeks with substances or drugs that may either induce or significantly inhibit cytochrome P450 3A (ketoconazole, clarithromycin, erythromycin, fluconazole, diltiazem, verapamil, etc) 18. Pregnant or breast feeding 19. Patients with galactose intolerance or malabsorption (as production of the drug contains lactose) 20. HbA1Cc ≥ 9 % 21. Serious medical illness (e.g. heart failure, severe pulmonary disorders, alcohol dependence, malignant tumors, etc) |
结果
主要结果指标
1. the change in the average daily area under the curve (AUC) for the serum sodium concentration from baseline to day 28 after intervention [baseline and 28 days]
次要成果指标
1. the change in the average daily area under the curve (AUC) for the serum sodium concentration from baseline to day 4 [baseline and 4 days]
2. the time to normalization of the serum sodium concentration [up to 28 days]
3. the time to first paracentesis, number of paracentesis, the volume of ascitic fluid obtained from paracentesis [up to 28 days]
4. Abdominal discomfort based on a 100-mm visual analogue scales (VAS) [day 1, 2, 3, 4, 7, 14, 21, 28]
5. The change in the dose of concomitant diuretics from baseline at day 28 [day 1, 2, 3, 4, 7, 14, 21, 28]
6. the number of participants with serious adverse events [from baseline to day 28 after intervention]
7. the time to ascites improvement [up to 28 days]
8. the time of worsening of ascites [up to 28 days]
